- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Neurocrine Biosciences Inc
+ Add to WatchlistNBIX:US
11.7500 USD 0.2400 2.00%As of 20:10:00 ET on 05/17/2013.
Snapshot for Neurocrine Biosciences Inc (NBIX)
| Open: | 12.0200 | Day's Range: | 11.6810 - 12.0999 | Volume: | 862,897 |
|---|---|---|---|---|---|
| Previous Close: | 11.7500 | 52wk Range: | 6.2500 - 12.8500 | 1-Yr Rtn: | +79.39% |
Key Statistics for NBIX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.1100 |
| Est. EPS (USD) (12/2013) | -0.7660 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 784.11 |
| Shares Outstanding (M) | 66.73 |
| 30 Day Average Volume | 570,454 |
| Price/Book (mrq) | 5.4078 |
| Price/Sale (ttm) | 18.3053 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/31/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for NBIX
Company Profile & Key Executives for NBIX
Neurocrine Biosciences, Inc. is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The Company is developing therapeutic interventions for anxiety, depression, Alzheimer's disease, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity, and diabetes.
| Kevin C GormanPresident/CEO | Timothy P CoughlinChief Financial Officer |
| Christopher F O'BrienChief Medical Officer | Haig P BozigianChief Development Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
NBIX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page